Wednesday, December 8, 2010

Two Treatments For Macular Degeneration – At Wildly Divergent Costs

Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. More than 1 million Americans have neovascular or “wet” AMD and a slightly lower number have “dry” AMD which often progresses to the more severe “wet” form. Since this is a disease of aging, we can expect many more cases as the population expands in the coming years.

Neovascular AMD appears to be related, at lease in part, to excess production of vascular endothelial growth factor (VEGF-A.) A specially developed monoclonal antibody called ranibizumab is available and approved by the FDA for wet AMD. The monoclonal antibody binds to VEGF-A, blocking function and thereby allowing healing of the retina. As a result of decreased vessel growth and decreased leakage, vision can stabilize and frequently actually improve. (See the clinical therapeutics article by Folk and Stone in the New England Journal of Medicine 2010; 363:1648 - 1655 for more details.)

Ranibizumab is injected directly into the eye and an effective concentration lasts for about 30 days. Although not a trivial procedure, it is straight forward in experienced hands and takes but a few minutes in an outpatient setting under topical and local anesthesia. The procedure is repeated in four weeks and in four weeks again. If vision has stabilized or even improved, then the next visit is scheduled in five weeks, then six weeks, etc. It appears that most treatment failures relate to missed follow-ups so attention to timing is very critical.

There is another anti VEGF-A monoclonal antibody, called bevacizumab, approved by the FDA for use in metastatic colon cancer treatment. It costs about $75 for a 1.25 milligram dose whereas ranibizumab costs about $2000 for a comparable dose (0.5 mg.) Although clearly an “off label” use, many retinal specialists will offer bevacizumab as an alternative to ranibizumab and let the patients ultimately decide. Trials comparing the two drugs are underway with results expected in less than a year.

What is clear now is the intraocular injections of anti-VEGF-A monoclonal antibody has substantial efficacy with limited risk.


Samual said...

Its a wonderful Blog.Lung cancer hospital India help clients with accommodation, visa documentation and tourist assistance.And provides treatment with advanced technology.

seoservices said...

I have been reading a lot of stuff about it. but it is different presented, i loved to read this. keep it up .
Text The Romance Back


HEy, I am agree with your Blog.
Black Belt Six Sigma Online Certification

Play Rummy said...

Hi , i got this Article , i was searching some thing relevant to this, And i am feeling lucky, as its the perfect one for what i am looking for. I will share this link on face book.

john smith said...

Such a inspirable and good post . I got new knowledge able while reading this . Keep sharing this type of post.Artificial Jewellery

Ricky jordan said...

I am agree with your Blog.Thanks for the useful information.I have been reading a lot of stuff about it. but the way in it is presented is nice.

Mike Steve said...

Thanks for the update.There is a scope to reach out for the best with the power of information in our hands that i got from your post.

website design company

sarabrook11 said...

Very true.Such a nice concept. Your information is true up to great most of the extent. Thanks for sharing.Thanks for the useful information.Such a inspirable and good post . I am able to get new knowledge while reading this . Keep sharing this type of informative posts.

web video production

Jaqulin Farnandez said...

Thank you so much for these information on macular degeneration. My grandmother is king of havinf eyesight problem due to her age. So we are trying to make her eyesight more better. Recently we have heard that there is this treatment named MS & macular degeneration treatment which is really effective. So we will give her this treatment.

Praise for Dr Schimpff

The craft of science writing requires skills that are arguably the most underestimated and misunderstood in the media world. Dumbing down all too often gets mistaken for clarity. Showmanship frequently masks a poor presentation of scientific issues. Factoids are paraded in lieu of ideas. Answers are marketed at the expense of searching questions. By contrast, Steve Schimpff provides a fine combination of enlightenment and reading satisfaction. As a medical scientist he brings his readers encyclopedic knowledge of his subject. As a teacher and as a medical ambassador to other disciplines he's learned how to explain medical breakthroughs without unnecessary jargon. As an advisor to policymakers he's acquired the knack of cutting directly to the practical effects, showing how advances in medical science affect the big lifestyle and economic questions that concern us all. But Schimpff's greatest strength as a writer is that he's a physician through and through, caring above all for the person. His engaging conversational style, insights and fascinating treasury of cutting-edge information leave both lay readers and medical professionals turning his pages. In his hands the impact of new medical technologies and discoveries becomes an engrossing story about what lies ahead for us in the 21st century: as healthy people, as patients of all ages, as children, as parents, as taxpayers, as both consumers and providers of health services. There can be few greater stories than the adventure of what awaits our minds, bodies, budgets, lifespans and societies as new technologies change our world. Schimpff tells it with passion, vision, sweep, intelligence and an urgency that none of us can ignore.

-- N.J. Slabbert, science writer, co-author of Innovation, The Key to Prosperity: Technology & America's Role in the 21st Century Global Economy (with Aris Melissaratos, director of technology enterprise at the John Hopkins University).